This comprehensive volume offers a complete and up-to-date overview of dermatologic therapeutics, including the latest advancements in the field. Each drug is presented in a concise and structured format—covering its introduction, mechanism of action, pharmacokinetics, indications, contraindications, clinical uses, and adverse effects. Special attention is given to its use in pregnancy, lactation, as well as in pediatric and geriatric populations.
Focusing on topical therapies, this book serves as an essential resource for dermatologists, students, and healthcare professionals. Thoughtfully designed flow diagrams throughout the text enhance understanding and bring clarity to complex concepts, reflecting the author’s practical insights and clinical experience. This is volume 3 of the set of three volumes.
Section XV Topical calcineurin inhibitors.
Chapter 89 Tacrolimus and
pimecrolimus.- Section XVI Topical retinoids.
Chapter 90 Tretinoin.-
Chapter 91 Tazarotene.
Chapter 92 Adapalene.
Chapter 93 Bexarotene.-
Chapter 94 Trifarotene.- Section XVII Topical glucocorticoids.
Chapter 95
Topical glucocorticoids.- Section XVIII Topical antifungals.
Chapter 96
Azoles.
Chapter 97 Terbenafine.
Chapter 98 Butenafine.
Chapter 99
Naftifine.
Chapter 100 Tavaborole.
Chapter 101 Selenium sulphide.-
Chapter 102 Ciclopirox.
Chapter 103 Amorolfine.
Chapter 104 Undecylenic
acid.- Section XIX Topical antiviral agents.
Chapter 105 Topical antiviral
agents.- Section XX Topical antibacterial agents.
Chapter 106 Mupirocin.-
Chapter 107 Bacitracin.
Chapter 108 Clindamycin.
Chapter 109
Erythromycin.
Chapter 110 Neomycin.
Chapter 111 Polymyxin B.
Chapter
112 Retapamulin.
Chapter 113 Silver sulfadiazine.
Chapter 114
Metronidazole.
Chapter 115 Ozenoxazin.- Section XXI Topical anti acne
drugs.
Chapter 116 Benzoyl peroxide.
Chapter 117 Azelaic acid.- Section
XXII Topical agents for pediculosis and scabies.
Chapter 118 Permethrin.-
Chapter 119 Spinosad.
Chapter 120 Malathion, Benzyl benzoate, Crotamiton,
Lindane.
Chapter 121 Abametapir.- Section XXIII Topical antipruritic
agents.
Chapter 122 Capsaicin.
Chapter 123 Dephenhydramine.
Chapter 124
Doxepin.
Chapter 125 Menthol.
Chapter 126 Phenol.
Chapter 127
Pramoxine.- Section XXIV Keratolytic agents.
Chapter 128 Salicylic acid.-
Chapter 129 Sulfur.
Chapter 130 Urea.- Section XXV Topical
chemotherapeutic agents.
Chapter 131 5-FU.
Chapter 132 Bleomycin.-
Chapter 133 Imiquimod (general).
Chapter 134 Imiquimod for malignant and
pre-malignant conditions.
Chapter 135 Tirbanibulin.- Section XXVI Topical
vitamin D analogues.
Chapter 136 Topical vitamin D analogues.- Section
XXVII Topical skin lightening agents.
Chapter 137 Hydroquinone.
Chapter
138 Mequinol.
Chapter 139 MBEH.
Chapter 140 Cysteamine.- Section XXVIII
Sunscreens.
Chapter 141 Sunscreens.- Section XIX Miscellaneous topical
agents.
Chapter 142 Anthralin.
Chapter 143 Podophyllin.
Chapter 144
Tar.
Chapter 145 Cantharidin.
Chapter 146 Crisaborole.- Section XXX
EMLA.
Chapter 147 EMLA.- Section XXXI Traditional therapies in
dermatology.
Chapter 148 Traditional therapies in dermatology.- Section
XXXII: Prostaglandin analogues.
Chapter 149 Latanoprost.
Chapter 150
Bimatoprost.- Section XXXIII Chemical peels.
Chapter 151 Glycolic acid.-
Chapter 152 Salicylic acid.
Chapter 153 Trichloroacetic acid.
Chapter 154
Lactic acid.
Chapter 155 Jessners peel.
Chapter 156 Mandelic acid.-
Chapter 157 Pyruvic acid.
Chapter 158 Tretinoin.- Section XXXIV
Photodynamic therapy.
Chapter 159 Photodynamic therapy.- Section XXXV
Botulinum Toxin.
Chapter 160 Botulinum Toxin.
Dr. Aditya Kumar Bubna is a Dermatologist, currently working as an Associate Professor in the Department of Dermatology, Katihar Medical College, Katihar, India. He has more than 50 publications in national and international journals. His particular interest is dermatologic therapeutics, with a keen interest on various pharmacologic and therapeutic aspects of dermatologic drugs, both topical and systemic. He feels that a thorough knowledge in this regard assists in the introduction of innovative strategies, that can significantly aid in reducing the frequency of conventional drug administration, thereby helping in alleviating the prevalence of side effects. He further percieves that safety and efficacy of drugs go hand in hand, when it comes to treating patients, and a thorough knowledge of these drugs therefore becomes essential for all clinicians.
His other interest in this field includes dermatopathology, an indispensable facet of diagnostic dermatology.
Lisainfo e-raamatute kohta